Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Pozenveo (poziotinib) / Assertio

NCT05045404: Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer

Withdrawn

Poziotinib Hydrochloride, 1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE

M.D. Anderson Cancer Center

Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8

02/23

ZENITH20, NCT03318939 / 2018-001868-36: Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

	Data from ZENITH20 trial for treatment-naïve and previously treated NSCLC at ESMO 2022
	Sep 2022 - Sep 2022: Data from ZENITH20 trial for treatment-naïve and previously treated NSCLC at ESMO 2022
	Presentation of data from of ZENITH20 trial in G778_P780dup HER2 Exon 20 Insertion Mutations NSCLC at ESMO 2022
	Sep 2022 - Sep 2022: Presentation of data from of ZENITH20 trial in G778_P780dup HER2 Exon 20 Insertion Mutations NSCLC at ESMO 2022
	Data from ZENITH20 trial for NSCLC at ESMO TAT virtual congress 2021
	Mar 2021 - Mar 2021: Data from ZENITH20 trial for NSCLC at ESMO TAT virtual congress 2021
	Data from cohort 3 of ZENITH20 trial for EGFR or HER2 exon 20 insertion mutation NSCLC
	Dec 2020 - Dec 2020: Data from cohort 3 of ZENITH20 trial for EGFR or HER2 exon 20 insertion mutation NSCLC
	Data from cohort 5 of ZENITH20 trial for EGFR or HER2 exon 20 insertion mutation NSCLC
	Dec 2020 - Dec 2020: Data from cohort 5 of ZENITH20 trial for EGFR or HER2 exon 20 insertion mutation NSCLC
	Data from cohort 2 of ZENITH20 trial for EGFR or HER2 exon 20 insertion mutation NSCLC
	Jul 2020 - Jul 2020: Data from cohort 2 of ZENITH20 trial for EGFR or HER2 exon 20 insertion mutation NSCLC
	From ZENITH20 trial in EGFR exon 20 insertion mutated NSCLC at ASCO 2020
	Jun 2020 - Jun 2020: From ZENITH20 trial in EGFR exon 20 insertion mutated NSCLC at ASCO 2020
	For 2L NSCLC patients with EGFR exon 20 insertion mutations
	Dec 2019 - Dec 2019: For 2L NSCLC patients with EGFR exon 20 insertion mutations
More

Terminated

648

Europe, Canada, US, RoW

Poziotinib

Spectrum Pharmaceuticals, Inc

NSCLC

04/23

NCT03744715 / 2020-005213-40: A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

Terminated

Poziotinib

Spectrum Pharmaceuticals, Inc

NSCLC, Breast Cancer

03/23

NCI-2017-00831, NCT03066206: Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

	Updated data from P2 trial in NSCLC with exon 20 mutations at WCLC 2018
	Sep 2018 - Sep 2018: Updated data from P2 trial in NSCLC with exon 20 mutations at WCLC 2018
	In patients with EGFR exon 20 mutations
	Sep 2018 - Sep 2018: In patients with EGFR exon 20 mutations
	In patients with EGFR exon 20 mutations
	Apr 2018 - Apr 2018: In patients with EGFR exon 20 mutations
	Interim data presentation for NSCLC at World Lung Conference 2017 in Japan [screenshot]
	Oct 2017 - Oct 2017: Interim data presentation for NSCLC at World Lung Conference 2017 in Japan [screenshot]
More

Active, not recruiting

Poziotinib, HM781-36B, NOV120101

M.D. Anderson Cancer Center, National Cancer Institute (NCI), Spectrum Pharmaceuticals, Inc

EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7

12/25

NCT04402008: Study of Poziotinib in Japanese Patients With NSCLC

Terminated

1/2

Japan

Poziotinib Once Daily Dosing, Poziotinib Twice Daily Dosing, Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1

Spectrum Pharmaceuticals, Inc

NSCLC

02/23



	Diseases Companies Products Productz Mechanisms of Action Sites